Tags

Type your tag names separated by a space and hit enter

Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
J Pharmacol Exp Ther. 1997 May; 281(2):730-7.JP

Abstract

Intrathecal administration of delta 9-tetrahydrocannabinol (delta 9-THC) but not the cannabinoid agonist CP55,940 enhances the antinociception produced by morphine. In addition, CP55,940- and delta 9-THC-induced antinociception is blocked by the kappa opioid antagonist norbinaltorphimine, and both cannabinoids are cross-tolerant to kappa agonists but do not act directly at the kappa receptor. Previous work in our laboratory has implicated dynorphins in the antinociceptive effects of delta 9-THC and its enhancement of morphine-induced antinociception. The goal of the present study was to evaluate the role of dynorphins in the antinociceptive effects of CP55,940 at the spinal level. Pretreatment of mice with antisera to dynorphin A(1-17), dynorphin A(1-8) or alpha-neoendorphin, all of which have been shown to retain specificity for blockade of their respective peptide in vivo, blocked the antinociceptive effects of delta 9-THC but not CP55,940. Dynorphin B produced antinociceptive effects on intrathecal administration to mice. Like CP55,940, dynorphin B failed to enhance the antinociceptive effects of morphine, whereas dynorphin A(1-17) and alpha-neoendorphin enhanced the antinociceptive effects of morphine. Using spinal catheterization of the rat, CP55,940 administration was shown to produce a significant release of dynorphin B concurrent with the production of antinociception. Our data suggest that CP55,940 induces a release of spinal dynorphin B that contributes at least in part to its antinociceptive effects in the spinal cord.

Authors+Show Affiliations

Department of Pharmacology and Toxicology, Medical College of Virginia/Virginia Commonwealth University, Richmond, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9152379

Citation

Pugh, G, et al. "Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord." The Journal of Pharmacology and Experimental Therapeutics, vol. 281, no. 2, 1997, pp. 730-7.
Pugh G, Mason DJ, Combs V, et al. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther. 1997;281(2):730-7.
Pugh, G., Mason, D. J., Combs, V., & Welch, S. P. (1997). Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. The Journal of Pharmacology and Experimental Therapeutics, 281(2), 730-7.
Pugh G, et al. Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord. J Pharmacol Exp Ther. 1997;281(2):730-7. PubMed PMID: 9152379.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. AU - Pugh,G,Jr AU - Mason,D J,Jr AU - Combs,V, AU - Welch,S P, PY - 1997/5/1/pubmed PY - 2001/3/28/medline PY - 1997/5/1/entrez SP - 730 EP - 7 JF - The Journal of pharmacology and experimental therapeutics JO - J Pharmacol Exp Ther VL - 281 IS - 2 N2 - Intrathecal administration of delta 9-tetrahydrocannabinol (delta 9-THC) but not the cannabinoid agonist CP55,940 enhances the antinociception produced by morphine. In addition, CP55,940- and delta 9-THC-induced antinociception is blocked by the kappa opioid antagonist norbinaltorphimine, and both cannabinoids are cross-tolerant to kappa agonists but do not act directly at the kappa receptor. Previous work in our laboratory has implicated dynorphins in the antinociceptive effects of delta 9-THC and its enhancement of morphine-induced antinociception. The goal of the present study was to evaluate the role of dynorphins in the antinociceptive effects of CP55,940 at the spinal level. Pretreatment of mice with antisera to dynorphin A(1-17), dynorphin A(1-8) or alpha-neoendorphin, all of which have been shown to retain specificity for blockade of their respective peptide in vivo, blocked the antinociceptive effects of delta 9-THC but not CP55,940. Dynorphin B produced antinociceptive effects on intrathecal administration to mice. Like CP55,940, dynorphin B failed to enhance the antinociceptive effects of morphine, whereas dynorphin A(1-17) and alpha-neoendorphin enhanced the antinociceptive effects of morphine. Using spinal catheterization of the rat, CP55,940 administration was shown to produce a significant release of dynorphin B concurrent with the production of antinociception. Our data suggest that CP55,940 induces a release of spinal dynorphin B that contributes at least in part to its antinociceptive effects in the spinal cord. SN - 0022-3565 UR - https://www.unboundmedicine.com/medline/citation/9152379/Involvement_of_dynorphin_B_in_the_antinociceptive_effects_of_the_cannabinoid_CP55940_in_the_spinal_cord_ L2 - https://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=9152379 DB - PRIME DP - Unbound Medicine ER -